49 min

Research Data Validates the Value of Pharmacists Providing Consult Reports to Support Pharmacogenomics Report Interpretation: An Interview with the Research Investigators PGX for Pharmacists

    • Business

Significant challenges to widescale clinical implementation of PGx include a lack of physician experience using PGx test data or confidence in interpreting PGx test data and integrating the data into the medication therapy management process. For PGx to be most impactful, prescribers must consider PGx data within the context of other non-genetic patient-specific factors. Pharmacists may help prescribers with PGx test data by creating a summary of medication therapy management recommendations for the patient that streamlines PGx report flags and identifies other pharmacotherapy interventions the pharmacist recognizes while applying non-genetic patient-specific data to the PGx test data.

In this episode of the PGx for Pharmacists podcast, Dr. Becky Winslow discusses the research study, "Pharmacist Consult Reports to Support Pharmacogenomics Report Interpretation," with two of the research investigators, Dr. Anna Langerveld and Dr. David Bright. Dr. Langerveld and Dr. Bright share how this research adds to the growing evidence that clinical pharmacists can help improve the utility of PGx and prescribing. They also share how their study described a process for reducing PGx laboratory report information to a single page of patient-specific clinical recommendations. Lastly, they share that while clinical decision support tools are becoming more routine for pharmacogenomic management, the pharmacists in this study reduced the number of report-based alerts independent of sophisticated clinical decision support informatics.

Anna Langerveld, Ph.D., is the Founder and President of Genemarkers, a contract research organization and CLIA/CAP certified testing laboratory specializing in genomics. Anna received her B.A. in Psychology from SUNY Binghamton and her Ph.D. from the Interdisciplinary Program in Neurosciences at Tulane University. After receiving her Ph.D., Anna served as a Research Assistant Professor at Western Michigan University. She founded Genemarkers in 2008. Under her leadership, Michigan Celebrates Small Business recognized the Company as one of the Top 50 Michigan Companies to watch.
Anna is an author of peer-reviewed publications, an NIH grant recipient, and an invited speaker at a wide range of national meetings. Anna currently serves as an adjunct professor and an advisory board member for the Manchester University pharmacogenomics program and holds a community faculty position at the Western Michigan University Homer Stryker M.D. School of Medicine.
Anna has been instrumental in developing strategic community partnerships to implement the use of genomics in clinical care, with a particular focus on mental health and underserved populations.

Dr. David Bright is a Professor of Pharmacy at Ferris State University, where he has taught therapeutics and medication therapy management. He received his PharmD degree from the University of Toledo, completed a community pharmacy residency with Kroger Pharmacy and the University of Toledo, and served on the faculty at the Ohio Northern University as a community pharmacy residency program director. His research has primarily involved the pragmatic implementation and improvement of non-dispensing pharmacy services, particularly in the outpatient setting. Most recently, that has involved the integration of pharmacogenomics into clinical practice through community pharmacy and ambulatory care practice models.

Research discussed in the podcast episode:
Bright D, Saadeh C, DeVuyst-Miller S, Sohn M, Choker A, Langerveld A. Pharmacist Consult Reports to Support Pharmacogenomics Report Interpretation. Pharmgenomics Pers Med. 2020 Dec 10;13:719-724. doi: 10.2147/PGPM.S276687. PMID: 33328756; PMCID: PMC7735940. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735940/
Learn more about your ad choices. Visit megaphone.fm/adchoices

Significant challenges to widescale clinical implementation of PGx include a lack of physician experience using PGx test data or confidence in interpreting PGx test data and integrating the data into the medication therapy management process. For PGx to be most impactful, prescribers must consider PGx data within the context of other non-genetic patient-specific factors. Pharmacists may help prescribers with PGx test data by creating a summary of medication therapy management recommendations for the patient that streamlines PGx report flags and identifies other pharmacotherapy interventions the pharmacist recognizes while applying non-genetic patient-specific data to the PGx test data.

In this episode of the PGx for Pharmacists podcast, Dr. Becky Winslow discusses the research study, "Pharmacist Consult Reports to Support Pharmacogenomics Report Interpretation," with two of the research investigators, Dr. Anna Langerveld and Dr. David Bright. Dr. Langerveld and Dr. Bright share how this research adds to the growing evidence that clinical pharmacists can help improve the utility of PGx and prescribing. They also share how their study described a process for reducing PGx laboratory report information to a single page of patient-specific clinical recommendations. Lastly, they share that while clinical decision support tools are becoming more routine for pharmacogenomic management, the pharmacists in this study reduced the number of report-based alerts independent of sophisticated clinical decision support informatics.

Anna Langerveld, Ph.D., is the Founder and President of Genemarkers, a contract research organization and CLIA/CAP certified testing laboratory specializing in genomics. Anna received her B.A. in Psychology from SUNY Binghamton and her Ph.D. from the Interdisciplinary Program in Neurosciences at Tulane University. After receiving her Ph.D., Anna served as a Research Assistant Professor at Western Michigan University. She founded Genemarkers in 2008. Under her leadership, Michigan Celebrates Small Business recognized the Company as one of the Top 50 Michigan Companies to watch.
Anna is an author of peer-reviewed publications, an NIH grant recipient, and an invited speaker at a wide range of national meetings. Anna currently serves as an adjunct professor and an advisory board member for the Manchester University pharmacogenomics program and holds a community faculty position at the Western Michigan University Homer Stryker M.D. School of Medicine.
Anna has been instrumental in developing strategic community partnerships to implement the use of genomics in clinical care, with a particular focus on mental health and underserved populations.

Dr. David Bright is a Professor of Pharmacy at Ferris State University, where he has taught therapeutics and medication therapy management. He received his PharmD degree from the University of Toledo, completed a community pharmacy residency with Kroger Pharmacy and the University of Toledo, and served on the faculty at the Ohio Northern University as a community pharmacy residency program director. His research has primarily involved the pragmatic implementation and improvement of non-dispensing pharmacy services, particularly in the outpatient setting. Most recently, that has involved the integration of pharmacogenomics into clinical practice through community pharmacy and ambulatory care practice models.

Research discussed in the podcast episode:
Bright D, Saadeh C, DeVuyst-Miller S, Sohn M, Choker A, Langerveld A. Pharmacist Consult Reports to Support Pharmacogenomics Report Interpretation. Pharmgenomics Pers Med. 2020 Dec 10;13:719-724. doi: 10.2147/PGPM.S276687. PMID: 33328756; PMCID: PMC7735940. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735940/
Learn more about your ad choices. Visit megaphone.fm/adchoices

49 min